|Trade names||Signifor, Signifor LAR|
|Drug class||Somatostatin analog|
|Main uses||Cushing's disease, acromegaly|
|Side effects||High blood sugar, diarrhea, abdominal pain, nausea, gallstones, injection site reactions, tiredness|
|Subcutaneous injection, intramuscular injection|
|Chemical and physical data|
|Molar mass||1047.227 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Pasireotide, sold under the brand name Signifor, is a medication used to treat Cushing's disease and acromegaly. It is used in Cushing's disease when surgery is not effective, and in acromegaly when neither surgery nor another somatostatin is effective. It is given by injection under the skin or into a muscle.
Common side effects include high blood sugar, diarrhea, abdominal pain, nausea, gallstones, injection site reactions, and tiredness. Other side effects may include low cortisol, slow heart rate, and liver problems. It is a somatostatin analog which blocks the release of growth hormone and cortisol.
Pasireotide was approved in Europe and the United States in 2012. In the United Kingdom it costs the NHS about £2,300 to £3,200 a month as of 2021. In the United States this amount costs about 15,300 USD.
For Cushing's it is used at a dose of 600 mcg injected under the skin twice per day; which may be increased to 900 mcg twice per day. A long acting formulation into a muscle every 4 weeks at a dose of 10 to 40 mg may also be used.
For acromegaly injections of 40 to 60 mg into a muscle every 4 weeks may be used.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 995. ISBN 978-0857114105.
- "Signifor EPAR". European Medicines Agency (EMA). Retrieved 13 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Pasireotide Monograph for Professionals". Drugs.com. Retrieved 26 October 2021.
- "Signifor Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 26 October 2021.
- "Pasireotide Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 13 May 2020.
- "EU/3/09/671". European Medicines Agency. 17 September 2018. Retrieved 13 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- Mancini T, Porcelli T, Giustina A (October 2010). "Treatment of Cushing disease: overview and recent findings". Therapeutics and Clinical Risk Management. 6: 505–16. doi:10.2147/TCRM.S12952. PMC 2963160. PMID 21063461.
- "Signifor LAR (pasireotide) for injectable suspension". U.S. Food and Drug Administration (FDA). 1 March 2016. Retrieved 13 May 2020.
- Tucker ME (17 December 2014). "FDA Approves Pasireotide for Treating Acromegaly". Medscape. Retrieved 2 August 2015.
- "Drug Approval Package: Signifor (pasireotide) Injection NDA #200677". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 13 May 2020.
- "Summary of Product Characteristics: Signifor" (PDF). European Medicines Agency.